https://pubmed.ncbi.nlm.nih.gov/36560485/ covid-19

Review

Vaccines (Basel). 2022 Dec 5;10(12):2075.
doi: 10.3390/vaccines10122075.

COVID-19 Vaccines for Adults and Children with Autoimmune Gut or Liver Disease
Monika Peshevska-Sekulovska 1 2, Plamena Bakalova 1, Violeta Snegarova 3, Snezhina Lazova 4 5, Tsvetelina Velikova 2 6

Abstract

The SARS-CoV-2 pandemic raised many challenges for all patients with chronic conditions and those with autoimmune diseases, both adults and children. Special attention is paid to their immunological status, concomitant diseases, and the need for immunosuppressive therapy. All of these factors may impact their COVID-19 course and outcome. COVID-19 vaccination is accepted as one of the most successful strategies for pandemic control. However, individuals with immune-mediated chronic diseases, including autoimmune liver and gut diseases, have been excluded from the vaccine clinical trials. Therefore, we rely on real-world data from vaccination after vaccine approval for these patients to fill the evidence gap for the long-term safety and efficacy of COVID-19 vaccines in patients with autoimmune gut and liver diseases. Current recommendations from inflammatory bowel disease (IBD) societies suggest COVID-19 vaccination in children older than 5 years old, adults and even pregnant females with IBD. The same recommendations are applied to patients with autoimmune liver diseases. Nevertheless, autoimmune disease patients still experience high levels of COVID-19 vaccine hesitancy, and more studies have to be conducted to clarify this issue.